These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26334991)

  • 1. Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.
    Gutzwiller FS; Pfeil AM; Ademi Z; Blank PR; Braunhofer PG; Szucs TD; Schwenkglenks M
    Pharmacoeconomics; 2015 Dec; 33(12):1311-24. PubMed ID: 26334991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.
    Koiwa F; Yokoyama K; Fukagawa M; Terao A; Akizawa T
    Nephrology (Carlton); 2017 Apr; 22(4):293-300. PubMed ID: 27496336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
    Nguyen HV; Bose S; Finkelstein E
    BMC Nephrol; 2016 Apr; 17(1):45. PubMed ID: 27121505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR
    Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
    Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients.
    Cho JH; Jang HM; Jung HY; Choi JY; Park SH; Kim CD; Yang CW; Jin DC; Kim YL
    Clin Ther; 2018 Jan; 40(1):123-134. PubMed ID: 28291581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study.
    Covic AC; Sprague SM; Rastogi A; Ketteler M; Walpen S; Perrin A; Floege J
    Nephron; 2020; 144(9):428-439. PubMed ID: 32585670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
    J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
    Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of sevelamer in patients new to dialysis.
    Taylor MJ; Elgazzar HA; Chaplin S; Goldsmith D; Molony DA
    Curr Med Res Opin; 2008 Feb; 24(2):601-8. PubMed ID: 18205996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A; Al-Makki A; Sutton J; Shepler B
    Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.
    Floege J; Covic AC; Ketteler M; Rastogi A; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
    Kidney Int; 2014 Sep; 86(3):638-47. PubMed ID: 24646861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.
    Floege J; Covic AC; Ketteler M; Mann J; Rastogi A; Spinowitz B; Rakov V; Lisk LJ; Sprague SM
    Nephrol Dial Transplant; 2017 Nov; 32(11):1918-1926. PubMed ID: 28339993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.
    Ruggeri M; Bellasi A; Cipriani F; Molony D; Bell C; Russo D; Di Iorio B
    J Nephrol; 2015 Oct; 28(5):593-602. PubMed ID: 25027030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.
    Yang L; Chuen Tan S; Chen C; Wang X; Li X; Yang X
    Clin Ther; 2016 Nov; 38(11):2459-2467.e1. PubMed ID: 27751671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.
    Greig SL; Plosker GL
    Drugs; 2015 Apr; 75(5):533-42. PubMed ID: 25761962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
    Park H; Rascati KL; Keith MS; Hodgkins P; Smyth M; Goldsmith D; Akehurst R
    Value Health; 2011 Dec; 14(8):1002-9. PubMed ID: 22152168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.